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Abstract
Background—Opioid use disorders are a growing public health problem in the United States. 
Most women who are opioid dependent are of childbearing age and management of opioid 
dependence during pregnancy poses unique challenges. Assessment includes evaluation for 
addiction, withdrawal syndromes, and co-morbid psychiatric diagnoses. Consultation-liaison 
psychiatrists may also be involved in acute pain management, perinatal medication management, 
buprenorphine induction and stabilization. For the past four decades, the standard of care has 
included methadone maintenance, but the increasing use of buprenorphine creates new treatment 
issues and opportunities.
Objective—To educate consultation-liaison psychiatrists in emergency and obstetrical settings 
about the appropriate approach toward the evaluation and basic management of women with 
opioid dependence in pregnancy.
Method—The authors reviewed the consensus literature and all new treatment options on opioid 
dependence during pregnancy.
Discussion—In this review, the authors summarize known and emerging management strategies 
for opioid dependence in pregnancy pertinent to consultation-liaison psychiatrists.
Background
Opioid use disorders are a major public health problem in the United States and nearly 90% 
of all American female opioid users are of childbearing age.1 National surveys suggest that 
up to 4.4% of pregnant women ages 15–44 reported non-medical use of prescription opioids 
within the past year and even higher rates (15%) among pregnant teenagers ages 15–17 
Address and phone number for correspondence and reprint requests: Eliza M Park, MD, University of North Carolina, 
Department of Psychiatry, Campus Box 7305, Chapel Hill, NC 27599, Phone: (919) 966-4772, Fax: (919) 966-6735. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Disclosures
Drs. Park and Suzuki have no potential conflicts of interest to disclose. Dr. Meltzer-Brody receives research grant support from the 
NIH, Foundation of Hope and Astra Zeneca.
HHS Public Access
Author manuscript
Psychosomatics. Author manuscript; available in PMC 2017 February 08.
Published in final edited form as:













years old.2 Actual prevalence rates of non-medical use of opioids during pregnancy may be 
higher though difficult to establish due to underreporting.
Pregnant women with opioid dependence are less likely to engage in prenatal care, have 
higher rates of obstetric problems, and their neonates are at risk of multiple medical 
complications.3–5 Challenges in the management of this patient population include the 
medical risks of illicit substance use in pregnancy, psychological comorbidity, and the 
psychosocial stressors that frequently interfere with prenatal treatment and addiction 
recovery. Despite these obstacles, pregnant women can be highly motivated to reduce 
substance use and most women strive for healthier pregnancy, providing a unique window of 
opportunity for intervention in this population.6 Prior studies suggest that pregnant women 
struggling with addiction not only attempt to reduce their substance use, they also seek 
improved nutrition, sleep, and other life-style changes.7
Treatment of opioid use disorders during pregnancy is unique among other types of 
substances because of its long record of favorable maternal and neonatal outcomes.8 The 
availability of replacement therapy shifts the emphasis from an abstinence-only model to 
that of harm reduction and engagement in treatment. While the standard of care for opioid 
replacement therapy in pregnant women remains methadone, buprenorphine is now also a 
viable treatment option.5
This review will cover the evaluation and management of the opioid-dependent pregnant 
woman and will pay special focus on the use of buprenorphine due to emerging data 
showing its comparable efficacy and safety during pregnancy and decreased severity of fetal 
withdrawal symptoms.9 While other emerging treatment options for opioid dependence such 
as oral or intramuscular naltrexone are available, they will not be covered in this paper due 
to the lack of substantial safety data in pregnancy.
Definitions
Opioid use disorders are heterogeneous in nature, ranging from lower risk substance 
“misuse” problems to addiction. Addiction is a concept not defined by the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV-TR) and is characterized by a loss of 
psychological control and continued use of substances despite consequences.10 The DSM-
IV-TR defines substance dependence as a maladaptive pattern of substance use leading to 
clinically significant impairment along with tolerance and/or withdrawal following cessation 
of use.11 The DSM-IV-TR also defines substance abuse as a maladaptive pattern of repeated 
use leading to interpersonal problems or danger to self.11 Patients who engage in opioid 
misuse, non-medical opioid use, and aberrant drug taking encompass a larger population of 
people who may or may not meet criteria for DSM-IV-TR substance abuse or dependence.
Medical risks of opioids in pregnancy
As compared to other substances, the physiologic negative effects of opioid use during 
pregnancy are less clear.3 Intermittent therapeutic use has not demonstrated significant 
negative impact on maternal health. Oral opioids such as oxycodone are frequently 
prescribed for pain during pregnancy and delivery. Data on the teratogenic effects of opioids 
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are inconsistent and exposure to opioids during the first trimester may be associated with 
elevated risk of fetal congenital heart defects.12
Heavy, chronic opioid use is associated with increased rates of prematurity, intrauterine 
growth retardation, preeclampsia, spontaneous abortion and intrauterine death (see Table 1 
for risks of chronic opioid use on pregnancy outcomes).4 The cycle of repeated opioid 
intoxication and withdrawal leads to unstable serum levels of the opioid and increased fetal 
activity.13 Intravenous opioid use exposes the mother and fetus to risks of infectious diseases 
such as Human Immunodeficiency Virus (HIV) and hepatitis B and C.
Interestingly, many of the dangers associated with opioid use disorders may be due to the 
maladaptive behaviors resulting from the addiction. Women addicted to opioids are less 
likely to seek prenatal care and are more likely to contract infectious diseases and be in 
violent relationships.3, 4 They may be more likely to discover pregnancy later in gestation 
and are at higher risk of unplanned pregnancy.14 Furthermore, heroin use can disrupt the 
menstrual cycle, a phenomenon that may be reversed with methadone or buprenorphine 
stabilization and may increase the risk of unintended pregnancy during early recovery.15
For the pregnant opioid dependent patient, including those participating in opioid-
maintenance treatment, polysubstance use (most commonly nicotine, alcohol, 
benzodiazepines, cocaine) is prevalent.14, 16, 17 Isolating the teratogenic effects of any one 
substance is difficult as they are frequently taken in combination.
Evaluation for co-morbid psychiatric conditions
Pregnancy and the postpartum are periods of heightened sensitivity to psychiatric disorders 
which may complicate treatment of substance abuse.18 Between 56–73% of opioid 
dependent pregnant women have a co-morbid psychiatric disorder.19 Substance-abusing 
women are at higher risk for psychological distress than their non-using counterparts, and 
untreated axis I disorders in these women are associated with poorer maternal outcomes.20 
There are limited data on recommended treatments of psychiatric disorders in pregnant 
women with co-morbid opioid dependence. However, the authors of this article recommend 
concurrent management of psychiatric symptoms with treatment of the substance use 
disorder.21
When evaluating opioid-dependent pregnant women, clinicians should employ broad 
screening for all psychiatric disorders as previous studies have suggested elevated rates of 
multiple conditions in these women including depressive disorders, anxiety disorders, post-
traumatic stress disorder, and hypomania.18, 20
As with all pregnant women, clinicians must weigh the potential risk of 
psychopharmacologic intervention on fetal exposure with the benefits of reduced psychiatric 
illness and symptom burden. Pharmacologic interactions with methadone and buprenorphine 
must be considered when making medication choices, though a discussion of the specific use 
of psychotropic medications during pregnancy is outside the scope of this paper. In addition, 
non-pharmacologic approaches such as psychotherapy should be encouraged.18
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Following initial evaluation, every effort should be made to refer the opioid dependent 
pregnant women to a specialized pregnancy and addiction treatment program. Female 
substance users have higher rates of poverty, unemployment, and current and prior physical 
and sexual abuse.22 Their greater burden of psychosocial stressors is best supported by 
treatment within a multidisciplinary center with intensive social services support.
Management of opioid withdrawal
Opioid withdrawal manifests as autonomic, neurologic, and influenza-like symptoms, many 
of which can be confused with symptoms of normal pregnancy.23 Careful differentiation of 
these symptoms is needed to appropriately avoid and manage symptoms of withdrawal 
during pregnancy. In adults, opioid withdrawal is distinctly uncomfortable but not fatal. For 
fetuses and neonates, abrupt opioid reduction was historically associated with greater central 
nervous system stress,24 stillbirth,25 and rarely, death,4 although more recent data suggests 
that gradual opioid detoxification within a treatment center is not associated with worse fetal 
outcomes.26, 27
Management of Detoxification
Most opioid dependent women should be maintained on opioids during pregnancy. 
Detoxification is not routinely recommended by leading experts, such as researchers at the 
Center for Addiction and Pregnancy at the Johns Hopkins Bayview Medical Center, due to 
the high risk of drug relapse.21, 27 Opioid detoxification is also associated with risk of 
precipitating fetal distress24 and co-morbid alcohol or sedative/hypnotic dependence can 
greatly complicate withdrawal management. Most opioid-dependent women who present 
during pregnancy are referred to opioid maintenance therapy instead of detoxification but 
rates of referral for opioid maintenance treatment versus controlled detoxification are 
unknown.
In limited circumstances, opioid detoxification may be appropriate for the highly motivated 
patient with a strong preference to remain drug-free. In such instances, the safest option may 
be to refer these patients to specialized opioid detoxification treatment centers. Women with 
greater social support and access to residential treatment may be less likely to resume illicit 
opioid use although detoxification in these patients has not been adequately studied.
When indicated, opioid detoxification is recommended by the American Society of 
Addiction Medicine during the second trimester28 to avoid risk of miscarriage associated 
with first trimester withdrawal5, 27, 29 and potential risk of precipitating preterm labor after 
the 32nd week of gestation.6 Recent studies in women with uncomplicated pregnancies have 
demonstrated the safety of gradual detoxification with methadone or clonidine in highly 
monitored inpatient settings.26, 27 Although no standard protocols exist for opioid 
detoxification during pregnancy, the Center for Substance Abuse Treatment (CSAT), of the 
Substance Abuse and Mental Health Services Administration (SAMHSA), recommends 
methadone tapers of 1.0 to 2.5 mg per day for inpatients and by 2.5 to 10.0 mg per week for 
outpatients.30
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Pharmacologic Management with Methadone
The primary pharmacologic treatments for opioid dependence are methadone and 
buprenorphine. The National Institutes of Health Consensus Development Panel currently 
recommends methadone treatment offered through federally regulated clinics as the standard 
of care for pregnant women seeking opioid maintenance.21
Treatment with methadone has demonstrated reduced pregnancy complication, higher birth 
weights, decreased HIV risk behaviors, decreased crimes rates and improved adherence to 
prenatal care when provided as part of a comprehensive care program.4, 21, 31 In addition, 
the long half-life of methadone (24–36 hours)26 helps ensure consistent blood levels in the 
fetus.
For most pregnant women, methadone doses between 80–120mg per day are sufficient and 
equivalent to non-pregnant patients, though some women may require dosage adjustments 
during pregnancy.4 Progesterone enhances cytochrome p450 metabolism of methadone 
which leads to increased methadone clearance and decreased opioid levels during the third 
trimester when progesterone and estrogen levels are significantly elevated.23, 32 Decreased 
oral absorption, expanded volume of distribution, and reduced plasma protein binding during 
pregnancy may also contribute to reduced methadone levels during later pregnancy.33 
Dosage increases or split dosing may be necessary to avoid precipitation of cravings or 
withdrawal.
Pharmacologic Management with Buprenorphine
Recently, buprenorphine has emerged as an alternative to methadone due to its availability in 
office-based settings, shorter duration and lessened intensity of neonatal withdrawal, and 
unique pharmacologic properties.6, 21 Buprenorphine is a partial mu-opioid receptor agonist 
and kappa-opioid antagonist with a long half-life of 24–60 hours.34 Induction with 
buprenorphine is more complicated than methadone due to the potential risk of precipitating 
withdrawal. Most non-pregnant patients are stabilized on daily doses of 4–24mg, though no 
guidelines exist on appropriate doses during pregnancy.21, 35 Unlike methadone, treatment 
with buprenorphine is less likely to require dosage adjustments during pregnancy, though the 
mechanism for this remains unknown.21 Transitioning from methadone to buprenorphine is 
possible though not routinely recommended.36
SAMHSA recommends buprenorphine monotherapy (Subutex®) instead of Buprenorphine/
Naloxone (Suboxone®) for pregnant women due to the lack of controlled studies using 
Suboxone. Jones et al. recommend avoidance of Suboxone to reduce risk of teratogenicity 
associated with naloxone, which may produce changes in maternal luteinizing hormone.21 In 
addition, inappropriate use of Suboxone via injection could precipitate opioid withdrawal 
due to the intravenous bioactivity of naloxone.35 Women who conceive while on Suboxone 
replacement therapy should be switched to Subutex for the duration of the pregnancy, 
despite the potential increased risk of medication misuse.21, 35 Several studies have revealed 
small numbers of pregnancies conceived during low dose (6–12mg/day) buprenorphine 
maintenance therapy without complications.37
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Initial studies of buprenorphine demonstrated its safety and tolerability in pregnancy,38, 39 
but studies directly comparing methadone and buprenorphine treatment were limited by 
small sample sizes or open label design.40–43 To address this, researchers at Johns Hopkins 
and across 8 international sites conducted the Maternal Opioid Treatment Experimental 
Research (MOTHER) trial, a double-blind, double-dummy, randomized controlled trial of 
175 pregnant women comparing buprenorphine with methadone for the treatment of opioid 
dependence in pregnancy through 28 days postpartum. There were no differences in 
maternal outcomes – including caesarian section rates, study discontinuation, anesthesia, and 
medical complications – between the two groups.9 Study outcomes related to the 
development and presentations of fetal withdrawal symptoms are discussed in the next 
section below. There was a higher rate of subject dissatisfaction with buprenorphine – a 
phenomenon that may have been related to the low induction doses of buprenorphine.
Neonatal abstinence syndrome and fetal risks of opioid treatment
Opioid maintenance treatment is not without risk. The most significant adverse effect 
associated with both methadone and buprenorphine treatment is fetal withdrawal. Other side 
effects associated with treatment include alterations in fetal activity and heart rate21, 44 as 
well as intrauterine growth restriction.45 The consequences of opioid-induced changes in 
fetal activity and heart rate are not well known.
Longitudinal studies of prenatal heroin or methadone exposure on infant developmental 
outcomes have yielded conflicting results.22 Differentiating the opioid effects from 
confounding factors has shown to be challenging in this clinical population. In addition, 
individual opioids have different affinities for receptors and receptor subtypes (e.g. 
methadone affects mu-opioid receptors as well as NMDA receptors), making comparisons 
between opioid exposures difficult.46, 47 Some studies demonstrate long-lasting depressed 
psychomotor performance and behavioral abnormalities detected at school age48–50 while 
other studies show much less severe outcomes, especially when comparing children from 
similar socio-economic groups.51 Animal models suggest neurobehavioral deficits can occur 
even without overall developmental retardation.52
When reviewing the pharmacologic options, clinicians should inform patients that long-term 
studies of prenatal exposure of buprenorphine are in progress and there are fewer data 
relative to methadone. Table 2 provides additional information about fetal risks of 
methadone and buprenorphine exposure as compared to heroin. Further research should 
include a meta-analysis directly comparing outcomes on retention, relapse, and neonatal 
abstinence syndrome (NAS) between maintenance therapies, including buprenorphine, and 
no treatment.
Chronic exposure to any opioid during pregnancy can result in the development of NAS, a 
constellation of symptoms affecting the newborn’s central and autonomic nervous system 
that can occur hours to days following delivery.9 Symptoms of NAS include irritability, 
tremor, hypertonicity, vomiting, diarrhea, excessive crying, and rarely, seizures.53 
Witnessing these symptoms can be distressing for the parents. Involved clinicians can help 
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by educating and supporting the mother as well as Neonatal Intensive Care Unit (NICU) 
staff about these symptoms to help facilitate the mother’s involvement in her infant’s care.16
There is an unclear relationship between the severity and duration of NAS and methadone or 
buprenorphine dosage, though most infants will demonstrate at least some symptoms.16, 17 
NAS is also observed in response to withdrawal from other psychotropic substances such as 
benzodiazepines.3 Infants at risk of opioid-induced NAS frequently require NICU-level care 
and regular monitoring of opioid withdrawal symptoms.53 Common pharmacologic 
treatments of NAS include tincture of opium, morphine sulphate solution, or methadone.53
The MOTHER trial found that buprenorphine treatment resulted in a significant reduction in 
the severity and duration of NAS, compared to methadone treatment. The overall proportion 
of infants who developed NAS symptoms requiring opioid treatment (47% vs. 57%) did not 
differ between groups, nor did peak NAS scores differ significantly between the two 
treatment arms. However, infants exposed to buprenorphine required 89% less morphine 
(1.1mg vs. 10.4mg) and spent on average 43% less time in the hospital (10.0 vs. 17.5 days) 
and 58% less time receiving treatment for NAS.9
Labor & Delivery Management
Maintenance doses of methadone and buprenorphine do not provide adequate analgesia for 
labor pain.54 To avoid precipitating withdrawal, these medications may be continued during 
labor and delivery.
Women receiving opioid agonist treatment usually report elevated pain scores and 
demonstrate greater opioid requirements than substance-abusing women not maintained on 
opioids or a normal, control group.55, 56 In one study, women prescribed buprenorphine had 
50% higher opioid requirements (89.3mg Oxycodone equivalents vs. 60.9mg) following 
cesarean delivery compared to control patients without opioid dependence.55
Acute peripartum pain in the opioid-maintained patient can be safely treated with additional 
short-acting opioids and non-steroidal anti-inflammatory drugs (NSAIDs). Although 
buprenorphine’s pharmacology as a partial mu opioid-receptor agonist can potentially 
complicate acute treatment of pain, preliminary data supports the use of continued 
buprenorphine with adjunctive opioids for pain control during the peripartum period. Several 
small studies indicate that postpartum pain following vaginal delivery can be adequately 
managed using NSAIDs and oxycodone for breakthrough pain with typical doses.55, 57 In 
another study of both methadone and buprenorphine-maintained patients, the brief 
administration of morphine or acetaminophen with codeine was well tolerated in both 
groups.40 Most of these studies were limited by the absence of control groups. 
Buprenorphine can also be discontinued and pain treated with full opioid agonists, but 
stopping this medication does require re-induction when acute pain has resolved if the 
patient wishes to resume treatment. There are no studies that suggest that the brief use of 
additional opioids in the postpartum period in an opioid-maintained patient interferes with 
her recovery from addiction.
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Use of regional analgesia such as epidural opioid anesthesia is an acceptable method of pain 
control, and is preferable to systemic opioid analgesia.1 To avoid the risk of precipitating 
withdrawal during labor, the high-affinity, partial opioid agonists such as nalbuphine 
(Nubain) should not be used if the patient is using lower-affinity full agonists such as 
methadone.58 When possible, developing a plan for pain management with the 
anesthesiologist prior to delivery is preferable.1
Following delivery, these women are at high risk of drug relapse. The prevalence of illicit 
drug use in new mothers is roughly equivalent to rates in non-pregnant women.2 Given the 
risk for relapse, further research and programs devoted to supporting women and stabilizing 
the postpartum home environment is needed.
Breastfeeding
Breastfeeding has multiple health benefits for infants and mothers.21 Breastfeeding with 
methadone is encouraged when the patient is HIV-seronegative and not abusing other 
substances and may even help ameliorate some symptoms of neonatal withdrawal.21, 58 The 
amount of methadone exposure in breast milk appears to be low and without direct 
correlation to maternal methadone dose.21 Breastfeeding with buprenorphine is also 
encouraged, though long-term data are lacking. Buprenorphine has poor oral bioavailability 
and the nursing infant is exposed to only 10–20% of total available drug.35 Therefore 
breastfeeding exposure to buprenorphine is unlikely to affect NAS.19, 21
Treatment resistance
Women who cannot remain abstinent from substances of abuse, despite knowledge of the 
potential harm to the fetus, represent a group with severe addiction. Treatment resistance can 
pose a major challenge in psychiatric evaluation and treatment. Expecting these women to 
remain abstinent for the duration of their pregnancy may be unrealistic and 
counterproductive.13 Stigmatizing or shaming patients during this time is harmful and will 
further increase resistance to treatment. Pregnant women experience greater rejection, blame 
and stigma than other populations with similar levels of substance use.59
Women’s fear of negative judgment as well as fear of prosecution can serve as a major 
barrier to care. When a pregnant woman admits to misusing or abusing substances, she is 
taking a major step towards treatment. Acknowledging the efforts that women take toward 
healthy behaviors is vital, especially when evaluating her in the emergency or medical 
settings. Empathic attitudes and facilitating treatment entry are among the primary goals of 
the consultant. Recognizing counter-transference and anticipating treatment-interfering 
behaviors can help not only the consultation-liaison psychiatrist, but also the obstetrical 
team when working with these patients. Strategies utilizing motivational interviewing or 
contingency management have also had some success with treatment engagement in this 
population though more research is needed.60
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Treatment of opioid-dependent pregnant women raises multiple ethical and legal questions 
for providers, particularly when the mother’s actions compromise the health of her 
pregnancy. Issues of confidentiality and patient autonomy become important aspects of the 
clinical encounter with these patients. Substance abuse testing and reporting laws for 
pregnant and postpartum women widely vary across the United States. Providers should 
have a clear understanding of their states laws and be prepared to discuss this with their 
patients. Fifteen states consider prenatal substance use child abuse and grounds for 
termination of parental rights.61 Three states can authorize civil commitment of prenatal 
users and mandate drug treatment.61 Misunderstanding about state policies may impede the 
patients’ willingness to openly discuss their substance use and engage in treatment.
Conclusions
Consultation-liaison psychiatrists should be knowledgeable about the acute evaluation and 
management of the opioid dependent pregnant patient. Goals of treatment include reducing 
fetal exposure to illicit substances, stabilizing the mother and fetus’ environment, avoidance 
of opioid withdrawal and increasing engagement in prenatal treatment. In contrast to the 
clinical management of other substances of abuse, abstinence is not the goal of treatment for 
the pregnant opioid dependent patient due to the high risk of relapse as well as the potential 
medical risks of opioid detoxification during pregnancy. Buprenorphine has emerged as a 
new and effective alternative to methadone maintenance treatment and represents an 
increasingly valuable option in the management of this population.
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Table 1
Risks of opioid dependence during pregnancy
Effects of opioid dependence on pregnancy outcomes Confounding factors associated with opioid dependence in pregnancy
Spontaneous abortion Poor nutrition
Preeclampsia29 Intimate partner violence
Intrauterine growth retardation Reduced prenatal care
Intrauterine death Polysubstance use
Preterm birth Co-morbid psychiatric illness
Low Apgar scores4 Infection (esp. with intravenous use)
Intrauterine passage of meconium4 Inadequate housing
Placental insufficiency29 Poverty
Premature rupture of membranes29 Poor dental hygiene4
Neonatal abstinence syndrome
Long-term neurobehavioral symptoms
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Table 2
Fetal effects of heroin as compared to methadone and buprenorphine
Heroin Methadone
(administered within a 
comprehensive program)
Buprenorphine
(administered within a 
comprehensive program)
Fetal pharmacokinetics Rapid transplacental passage,47 
short half-life increases risk of 
fluctuating fetal opioid levels
Rapid transplacental passage,47 
longer half-life reduces risk of 
unstable fetal opioid levels
Rapid transplacental 
passage,47 longer half-life 
reduces risk of unstable 
fetal opioid levels
Spontaneous abortion High (estimated 10–20%)23 Moderate, estimated 3–4%23 Unknown, possibly less 
than methadone23
Decreased heart rate and heart 
rate variability
Present Present, especially in third trimester44 Present, possibly less 
severe than methadone 
during first trimester44
Neonatal abstinence syndrome Common, rapid onset usually by 
24 hours58
More frequent than compared to 
heroin, often delayed onset >48 hours
Common, but less severe 
in intensity and duration 
than for methadone
Cognitive Short and long-term 
neuropsychiatric effects present 
but multiple confounders44
Short and long-term neuropsychiatric 
effects present but multiple 
confounders44
Neuropsychiatric effects 
present but multiple 
confounders. No long-term 
available data yet44
Premature delivery Increased risk, variable rates 
depending on confounding factors
Increased risk but less than heroin43 Increased risk but less than 
heroin, similar to 
methadone43
Impaired somatic growth Decreased head circumference, 
birth weight and intrauterine 
growth restriction,44 estimated 
relative risk of low birth weight is 
4.61 compared to non-drug using 
mothers6
Present but less severe than heroin,44 
estimated relative risk of low birth 
weight is 1.36 compared to non-drug 
using mothers6
Present but less severe 
than heroin. Similar effects 
relative to methadone44
Reduced fetal motor activity Present Present, especially in third trimester44 Present, possibly less 
severe than methadone 
during first trimester44













Park et al. Page 15
Table 3
Management of Opioid Dependence in Pregnancy: Key Points
• Most pregnant women with opioid dependence are unable to maintain abstinence from substances during pregnancy
• Uncontrolled opioid withdrawal during pregnancy should be avoided due to risks to the fetus
• Buprenorphine is an effective alternative to methadone maintenance treatment during pregnancy
• Treatment with buprenorphine maintenance therapy is associated with decreased severity and duration of neonatal abstinence 
syndrome
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